Kazia Therapeuti Stock Price, News & Analysis

Kazia Therapeutics announces progress in its pivotal GBM AGILE study for lead asset paxalisib, with data expected in CY23. Recent US C-suite appointments indicate a focus on commercialization. The second asset, EVT801, is in human trials, with the first patient enrolled in France. The company's valuation has increased to US$294m or US$22.28 per basic ADR, driven by NPV roll-forward, despite lower cash and higher R&D costs. Net cash stood at US$11.0m as of December 31, 2021, indicating a runway into H123.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced upcoming presentations at two key events. Scheduled for April 8-13, 2022, at the American Association of Cancer Research Annual Scientific Meeting in New Orleans, four abstracts related to their drug pipeline will be presented. This includes updates on EVT801 and paxalisib, both pivotal in treating advanced cancers. Additionally, CEO Dr. James Garner will discuss corporate progress at the 2022 Virtual Growth Conference from March 28-30, 2022. These presentations highlight Kazia's commitment to oncology research and drug development.

Kazia Therapeutics Limited (NASDAQ: KZIA) announces the initiation of a phase II clinical study of paxalisib combined with metformin and a ketogenic diet for treating glioblastoma at Weill Cornell Medicine. The trial will recruit 30-60 patients over two years, aiming to enhance treatment efficacy through a low-insulin state. Dr. Howard Fine will lead the trial, which is expected to yield significant data read-outs throughout 2022, including insights on progression-free survival. Kazia continues its commitment to advancing glioblastoma treatment, with multiple ongoing studies.

Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the BIO CEO Conference in New York from February 14-17, 2022. CEO Dr. James Garner will deliver an update on the company's clinical-stage oncology programs, including paxalisib, a treatment for glioblastoma, and EVT801, a small-molecule inhibitor targeting various tumor types. The conference, hosted by the Biotechnology Innovation Organization, connects biotech companies with investors and analysts. Attendees can register via the conference website.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced its CEO, Dr. James Garner, will speak at the virtual Edison Group 'Open House' Event from January 25-27, 2022. Kazia is among 33 healthcare companies participating in this event, showcasing innovations in pharmaceuticals and technology. The presentation will occur on January 26, with on-demand access available from 8 AM GMT. Interested investors can register for free here.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced that CEO Dr. James Garner will speak at the HC Wainwright BioConnect Conference from January 10-13, 2022. The event will feature over 275 companies from the life sciences sector and includes keynote speaker Scott Gottlieb, former FDA Commissioner. Dr. Garner's 'fireside chat' will be streamed online starting January 10 at 7 am ET, discussing Kazia's achievements in 2021 and anticipated milestones for 2022. Registration for the conference is free at hcwevents.com/bioconnect.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of Karen Krumeich as Chief Financial Officer, effective January 2022. With over 30 years of experience in corporate finance, particularly in life sciences, Krumeich aims to enhance relationships with US investors and prepare for company expansion. CEO James Garner emphasized the transformative period for Kazia, highlighting Krumeich's extensive background in biotech. Kazia is advancing its pipeline, which includes the leading drug paxalisib for glioblastoma and EVT801, with ongoing clinical studies.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced promising final results from its Phase II clinical study of paxalisib as a first-line treatment for glioblastoma (NCT03522298). The study involved 30 patients with newly diagnosed disease, revealing a median overall survival of 15.7 months, outperforming the historical 12.7 months with temozolomide. Progression-free survival was also notable at 8.4 months compared to 5.3 months for the standard treatment. The maximum tolerated dose of paxalisib was set at 60mg daily. Kazia aims to publish these findings in a peer-reviewed journal in 2022.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announces the opening of the GBM AGILE study in glioblastoma at Sunnybrook Health Sciences Centre in Toronto, marking Canada's first site for paxalisib recruitment. This expansion into Canada allows Canadian patients to access potential new treatment options for glioblastoma, which affects approximately 1,200 Canadians annually. The study aims to enroll up to 200 patients on paxalisib and will include sites in the US, with plans to expand to Europe and China in the coming months.